Author

K. Donckers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

D. Jochmans· 3 shared J. Neyts· 3 shared L. Vangeel· 2 shared N. Ebert· 2 shared S. De Jonghe· 2 shared V. Thiel· 2 shared A. Jekle· 1 shared A. K. Chatterjee· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. Jochmans

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters

R. Abdelnabi, D. Jochmans, K. Donckers, B. Trueeb, N. Ebert, B. Weynand, V. Thiel, J. Neyts

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

bioRxiv · Sep 28, 2022 · PreprintMicrobiology

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir

D. Jochmans, C. Liu, K. Donckers, A. Stoycheva, S. Boland, S. K. Stevens, C. De Vita, B. Vanmechelen, P. Maes, B. S. Trüeb, N. Ebert, V. Thiel, S. De Jonghe, L. Vangeel, D. Bardiot, , K. Vandyck

This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.

bioRxiv · Jun 7, 2022 · PreprintMicrobiology

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

T. N. D. Do, K. Donckers, L. Vangeel, A. K. Chatterjee, P. A. Gallay, M. D. Bobardt, J. P. Bilello, T. Cihlar, S. De Jonghe, J. Neyts, D. Jochmans

This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.

bioRxiv · Mar 25, 2021Microbiology